SBYSF
Sibanye Stillwater Ltd
$2.69
0.00%
No data for this timeframe.
Vol
SEC Reports6
Recent Activity
Jun 3, 2026
SEC
Sibanye Stillwater filed a Form 6-K on June 3, 2026, attaching a market release (Exhibit 99.1). The filing is a routine
6-K — Impact 2/10
Jun 2, 2026
SEC
Sibanye Stillwater Ltd filed a Form 6-K on June 2, 2026, attaching a market release (Exhibit 99.1). The filing is a rout
6-K — Impact 2/10
May 29, 2026
SEC
Sibanye Stillwater filed a Form 6-K on 29 May 2026, furnishing a market release as Exhibit 99.1. The filing is a routine
6-K — Impact 2/10
Analyst Ratings
1Strong Buy
4Buy
5Hold
1Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.0/10.
NEUTRAL
6-K
2/10
Sibanye Stillwater filed a Form 6-K on June 3, 2026, attaching a market release (Exhibit 99.1). The
Jun 3, 2026
NEUTRAL
6-K
2/10
Sibanye Stillwater Ltd filed a Form 6-K on June 2, 2026, attaching a market release (Exhibit 99.1).
Jun 2, 2026
NEUTRAL
6-K
2/10
Sibanye Stillwater filed a Form 6-K on 29 May 2026, furnishing a market release as Exhibit 99.1. The
May 29, 2026
BULLISH
6-K
7/10
Sibanye Stillwater released its 2025 financial results, reporting a 22% increase in EBITDA to $1.2 b
Apr 24, 2026
NEUTRAL
6-K
3/10
Sibanye Stillwater Ltd filed a Form 6-K to report the release of its Q1 2026 financial results, incl
Apr 20, 2026
NEUTRAL
6-K
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 45% buy across 11 analysts — 1 strong buy, 4 buy, 5 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $182.3B | 40.6% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $178.7B | -2.0% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 5 | 1 | 0 | 45% | |
| May 1, 2026 | 1 | 4 | 5 | 1 | 0 | 45% | |
| Apr 1, 2026 | 1 | 4 | 5 | 1 | 0 | 45% | |
| Mar 1, 2026 | 1 | 4 | 5 | 1 | 0 | 45% | |
| Feb 1, 2026 | 1 | 4 | 5 | 1 | 0 | 45% | |
| Jan 1, 2026 | 0 | 1 | 5 | 6 | 1 | 8% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.